A Phase 2 interventional study of EMA401 and Placebo in Painful Diabetic Neuropathy, sponsored by Novartis Pharmaceuticals. Terminated at 64 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
This was an interventional, randomized, parallel, placebo-controlled, double-blind treatment study consisting of 3 periods i.e. Screening, Treatment, and Treatment withdrawal. Patients were planned to be randomized in a 1:1 ratio to Placebo b.i.d. or EMA401 100 mg b.i.d.. Concomitant use of pregabalin or duloxetine at stable doses was allowed. Based on historical data, it was planned that the study would enroll approximately 50% of patients who were on stable doses of concomitant pregabalin or duloxetine in the study. At the end of treatment period the 100mg b.i.d. arm was re-randomized (1:1) to the same treatment or placebo. Placebo arm stayed on placebo. The planned duration of treatment period was 12 weeks and 1 week of treatment withdrawal at the end of treatment period.
The study was terminated early due to pre-clinical toxicity data that became available after start of trial. Novartis implemented a Urgent Safety Measure (USM) which instructed sites to discontinue study treatment immediately and to have all patients return for additional laboratory assessments (full hematology including coagulation and clinical chemistry panel). Safety data from the USM was presented as a separate outcome measure table and not included in the Adverse Event section
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
This study's enrollment of 142 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Browse Diabetic Neuropathies studies →Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At the time of Screening, must have had documented diagnosis of Type I OR Type II diabetes mellitus (DM) with painful distal symmetrical sensorimotor neuropathy (ICD-10 code G63.2) of more than 6 months duration with any one or more of the following:
Exclusion Criteria:
Women of , defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of during dosing and for 3 days after stopping of study medication. Highly effective contraception methods included:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
Drug: EMA401 · Drug: Placebo
Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
Drug: Placebo
capsules, oral
Placebo to EMA401 capsules, oral
Change in Weekly Mean 24-hour Average Pain Score Using the 11 Point Numerical Rating Scale (NRS) From Baseline to Week 12
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.
Time frame: Baseline up to Week 12
Change in Neuropathic Pain Symptom Inventory (NPSI) From Baseline to Week 12
The Neuropathic Pain Symptom Inventory (NPSI) is a 12 item patient reported outcome measure that contains 10 descriptors representing 5 dimensions of pain (burning pain, deep/pressing pain, paroxysmal pain, evoked pain and paraesthesia/dysesthesia) and 2 temporal items designed to assess pain duration and the number of pain paroxysms. The sum of the responses to the 10 questions (all except temporal questions) was regarded as the total score and was divided by 10 (10 questions). The range of the total score and of the 5 dimensional scores is 0 to 10. Lower values represent better outcomes.
Time frame: Baseline up to Week 12
Change in Brief Pain Inventory-Short Form Interference (BPI-SF) Mean Total Score From Baseline to Week 12
The BPI-SF is a validated, self-administered (at clinic) questionnaire that assesses pain severity and its mpact on daily functions. Patients were asked to complete the 7-item pain interference scale that assessed the degree to which pain interfered with walking and other physical activity, work, mood, relations with others and sleep using a zero to ten scale with zero being "does not interfere" and ten being "completely interferes". The BPI total score is the sum of the 7 items. Each item ranges from 0 to 10, thus the total score ranges from 0 to 70. Lower values indicate a better outcome.
Time frame: Baseline up to Week 12
Change in Weekly Mean of the 24-hour Worst Pain Score, Using an 11-point NRS, From Baseline to Week 12
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.
Time frame: Baseline up to Week 12
Number of Participants Per Patient Global Impression of Change Category at Week 12
The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse"). The PGIC is based on the validated Clinical Global Impression of Change scale. The PGIC was to be completed by patients using the electronic tablet at the site
Time frame: Baseline up to Week 12
Percentage of Patients Achieving at Least 30% Pain Reduction at Week 12 on NRS 11 Point Scale
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 30% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.
Time frame: Baseline up to Week 12
Percentage of Patients Achieving at Least 50% Pain Reduction at Week 12 on NRS 11 Point Scale
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 50% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.
Time frame: Baseline up to Week 12
Mean Change in Insomnia Severity Index (ISI) From Baseline to Week 12
Patients were asked to complete the ISI using five-point Likert-style scale as a measure of perceived sleep difficulties. The questionnaire assessed the severity of insomnia, satisfaction with current sleep pattern, sleep interference, "noticeability" of sleeping problem to others and concern about sleeping problems. The scale consists of 7 items. The sum of seven items represents the total score. Each of the 7 items is scored using a range from 0 to 4, thus the total score values ranges from zero to 28. Lower values represent better outcomes.
Time frame: Baseline up to Week 12
Plasma Pharmacokinetics (PK) Concentrations at Week 8 and 12
Due to the premature termination of the study, the number of patients and observations providing PK data was much smaller than planned, and no PK model was developed. As a consequence, no PK parameters (Cmax, Tmax, AUC) were derived for this study. Only, summary statistics of the plasma concentrations were calculated
Time frame: Week 8 (Prior dose, 1-3 hours, 4-6 hours), Week 12 (Prior dose, 1-3 hours, 4-6 hours)
Percentage of Patients Who Required Rescue Medication in Double-blind Treatment Period
Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.
Time frame: Baseline and weekly up to 12 weeks, once during double-blind period
Percentage of Patients Who Required Rescue Medication in Treatment Withdrawal Period
Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.
Time frame: Week 12 to Week 13 (planned duration subject to varibility in visit scheduling)
Time to First Rescue Medication Intake
Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Patients who did not take any rescue medication were censored at the last date of double-blind treatment period.
Time frame: Baseline up to day 92
Treatment Emergent Adverse Events During Urgent Safety Measure (USM) Follow-Up
Participants were instructed to stop taking drug immediately upon termination of study and asked to come in for two unscheduled visits for follow up safety assessments
Time frame: Approximately from 3 weeks after end of study up to 16 weeks
| Milestone | EMA401 100mg BID DB | Placebo BID DB | EMA401 100mg BID -> EMA401 100mg BID TW | EMA401 100mg BID -> Placebo BID TW | Placebo BID -> Placebo BID TW |
|---|---|---|---|---|---|
| Started | 70 | 67 | 0 | 0 | 0 |
| Completed | 32 | 30 | 0 | 0 | 0 |
| Not completed | 38 | 37 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 30 | 31 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 4 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 |
| Milestone | EMA401 100mg BID DB | Placebo BID DB | EMA401 100mg BID -> EMA401 100mg BID TW | EMA401 100mg BID -> Placebo BID TW | Placebo BID -> Placebo BID TW |
|---|---|---|---|---|---|
| Started | 0 | 0 | 14 | 12 | 27 |
| Completed | 0 | 0 | 14 | 11 | 27 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 1 | 0 |
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.
| scores on a scale | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Week 4 | -1.0 ± 0.21 | -0.8 ± 0.18 |
| Week 8 | -1.7 ± 0.29 | -1.1 ± 0.26 |
| Week 12 | -1.9 ± 0.31 | -1.3 ± 0.27 |
The Neuropathic Pain Symptom Inventory (NPSI) is a 12 item patient reported outcome measure that contains 10 descriptors representing 5 dimensions of pain (burning pain, deep/pressing pain, paroxysmal pain, evoked pain and paraesthesia/dysesthesia) and 2 temporal items designed to assess pain duration and the number of pain paroxysms. The sum of the responses to the 10 questions (all except temporal questions) was regarded as the total score and was divided by 10 (10 questions). The range of the total score and of the 5 dimensional scores is 0 to 10. Lower values represent better outcomes.
| scores on a scale | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Week 4 | -1.2 ± 0.19 | -1.0 ± 0.18 |
| Week 8 | -1.3 ± 0.25 | -0.9 ± 0.22 |
| Week 12 | -1.6 ± 0.32 | -1.1 ± 0.26 |
The BPI-SF is a validated, self-administered (at clinic) questionnaire that assesses pain severity and its mpact on daily functions. Patients were asked to complete the 7-item pain interference scale that assessed the degree to which pain interfered with walking and other physical activity, work, mood, relations with others and sleep using a zero to ten scale with zero being "does not interfere" and ten being "completely interferes". The BPI total score is the sum of the 7 items. Each item ranges from 0 to 10, thus the total score ranges from 0 to 70. Lower values indicate a better outcome.
| scores on a scale | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Change in Brief Pain Inventory-Short Form Interference (BPI-SF) Mean Total Score From Baseline to Week 12 | -12.03 ± 13.336 | -10.83 ± 14.602 |
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.
| scores on numeric rating scale | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Change in Weekly Mean of the 24-hour Worst Pain Score, Using an 11-point NRS, From Baseline to Week 12 | -1.63 ± 1.837 | -1.28 ± 1.577 |
The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse"). The PGIC is based on the validated Clinical Global Impression of Change scale. The PGIC was to be completed by patients using the electronic tablet at the site
| Participants | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Very much improved | 4 | 2 |
| Much improved | 7 | 11 |
| Minimally improved | 17 | 18 |
| No change | 18 | 14 |
| Minimally worse | 3 | 2 |
| Much worse | 0 | 0 |
| Very much worse | 0 | 0 |
| Missing | 21 | 20 |
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 30% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.
| % of participants - model adjusted rate | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Week 4 - at least 30% pain reduction | 34.0 | 24.7 |
| Week 12 - at least 30% pain reduction | 52.7 | 40.4 |
The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 50% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.
| % of participants - model adjusted rate | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Percentage of Patients Achieving at Least 50% Pain Reduction at Week 12 on NRS 11 Point Scale | 31.4 | 14.1 |
Patients were asked to complete the ISI using five-point Likert-style scale as a measure of perceived sleep difficulties. The questionnaire assessed the severity of insomnia, satisfaction with current sleep pattern, sleep interference, "noticeability" of sleeping problem to others and concern about sleeping problems. The scale consists of 7 items. The sum of seven items represents the total score. Each of the 7 items is scored using a range from 0 to 4, thus the total score values ranges from zero to 28. Lower values represent better outcomes.
| scores on a scale | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Mean Change in Insomnia Severity Index (ISI) From Baseline to Week 12 | -4.00 ± 4.854 | -1.03 ± 6.312 |
Due to the premature termination of the study, the number of patients and observations providing PK data was much smaller than planned, and no PK model was developed. As a consequence, no PK parameters (Cmax, Tmax, AUC) were derived for this study. Only, summary statistics of the plasma concentrations were calculated
| ng/mL | EMA401 100mg BID DB |
|---|---|
| Week 8 Prior dose | 30.5 ± 126.6 |
| Week 8 1-3 hours | 205.1 ± 212.8 |
| Week 8 4-6 hours | 72.8 ± 115.2 |
| Week 12 Prior dose | 29.5 ± 209.3 |
| Week 12 1-3 hours | 118.4 ± 278.3 |
| Week 12 4-6 hours | 89.8 ± 117.0 |
Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.
| Percentage of participants | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Week 1 | 13.0 | 10.6 |
| Week 2 | 7.7 | 9.5 |
| Week 4 | 8.6 | 7.0 |
| Week 6 | 7.8 | 7.5 |
| Week 8 | 9.3 | 9.5 |
| Week 10 | 5.3 | 13.2 |
| Week 12 | 2.9 | 8.6 |
| At least once during double-blind period | 20.0 | 19.4 |
Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.
| Percentage of participants | EMA401 100mg BID -> EMA401 100mg BID TW | EMA401 100mg BID -> Placebo BID TW | Placebo BID -> Placebo BID TW |
|---|---|---|---|
| Percentage of Patients Who Required Rescue Medication in Treatment Withdrawal Period | 14.3 | 8.3 | 7.4 |
Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Patients who did not take any rescue medication were censored at the last date of double-blind treatment period.
| days | EMA401 100mg BID DB | Placebo BID DB |
|---|---|---|
| Time to First Rescue Medication Intake | 44.0 (2 to 90) | 56.5 (2 to 92) |
Participants were instructed to stop taking drug immediately upon termination of study and asked to come in for two unscheduled visits for follow up safety assessments
| Participants | EMA401 100mg BID -> EMA401 100mg BID TW | EMA401 100mg BID -> Placebo BID TW | Placebo BID -> Placebo BID TW |
|---|---|---|---|
| Peritoneal adhesions | 1 | 0 | 0 |
| Cholelithiasis | 1 | 0 | 0 |
| Liver abscess | 1 | 0 | 0 |
| Blood creatinine increased | 0 | 0 | 1 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 21 days post treatment, up to maximum duration of 111 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EMA401 100mg BID DB | 0/69 (0%) | 5/69 (7.2%) | 23/69 (33.3%) |
| Placebo BID DB | 0/66 (0%) | 3/66 (4.5%) | 10/66 (15.2%) |
| EMA401 100mg BID -> EMA401 100mg BID TW | 0/14 (0%) | 0/14 (0%) | 1/14 (7.1%) |
| EMA401 100mg BID -> Placebo BID TW | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Placebo BID -> Placebo BID TW | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) |
| Event | EMA401 100mg BID DB | Placebo BID DB | EMA401 100mg BID -> EMA401 100mg BID TW | EMA401 100mg BID -> Placebo BID TW | Placebo BID -> Placebo BID TW |
|---|---|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 2/69 | 0/66 | 0/14 | 0/12 | 0/26 |
| Acute coronary syndromeCardiac disorders | 0/69 | 1/66 | 0/14 | 0/12 | 0/26 |
| ErysipelasInfections and infestations | 0/69 | 1/66 | 0/14 | 0/12 | 0/26 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/69 | 1/66 | 0/14 | 0/12 | 0/26 |
| Product intoleranceGeneral disorders | 1/69 | 0/66 | 0/14 | 0/12 | 0/26 |
| CholelithiasisHepatobiliary disorders | 1/69 | 0/66 | 0/14 | 0/12 | 0/26 |
| Localised infectionInfections and infestations | 1/69 | 0/66 | 0/14 | 0/12 | 0/26 |
| Event | EMA401 100mg BID DB | Placebo BID DB | EMA401 100mg BID -> EMA401 100mg BID TW | EMA401 100mg BID -> Placebo BID TW | Placebo BID -> Placebo BID TW |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/69 | 6/66 | 0/14 | 0/12 | 0/26 |
| Lipase increasedInvestigations | 6/69 | 0/66 | 1/14 | 0/12 | 0/26 |
| PalpitationsCardiac disorders | 0/69 | 1/66 | 0/14 | 1/12 | 0/26 |
| HypertensionVascular disorders | 1/69 | 2/66 | 0/14 | 1/12 | 0/26 |
| Abdominal pain upperGastrointestinal disorders | 5/69 | 0/66 | 0/14 | 0/12 | 0/26 |
| HeadacheNervous system disorders | 4/69 | 4/66 | 0/14 | 0/12 | 0/26 |
| NauseaGastrointestinal disorders | 4/69 | 1/66 | 0/14 | 0/12 | 0/26 |
| Gamma-glutamyltransferase increasedInvestigations | 4/69 | 1/66 | 0/14 | 0/12 | 0/26 |
| Age, Customized(Participants) | EMA401 100mg BID DB | Placebo BID DB | Total |
|---|---|---|---|
| 18 - 64 years | 34 | 33 | 67 |
| 65 - 84 years | 36 | 33 | 69 |
| ≥ 85 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | EMA401 100mg BID DB | Placebo BID DB | Total |
|---|---|---|---|
| Female | 20 | 24 | 44 |
| Male | 50 | 43 | 93 |
| Race/Ethnicity, Customized(Participants) | EMA401 100mg BID DB | Placebo BID DB | Total |
|---|---|---|---|
| Caucasian | 70 | 63 | 133 |
| Asian | 0 | 1 | 1 |
| Other | 0 | 3 | 3 |
| Body mass index(kg/m^2) | EMA401 100mg BID DB | Placebo BID DB | Total |
|---|---|---|---|
| Median | 30.8 (22.7 to 43.2) | 30.2 (19.5 to 48.2) | 30.6 (19.5 to 48.2) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Mar 2018 to primary completion in Mar 2019, 12 months.
Results were first posted in Jun 2020, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EMA400